



Project Proposal

Project Description (*max 500 words*)

The aim of our research is to understand the complex interaction between inherited genetic variation and that acquired at the tumor level and therefore to understand its effect on carcinogenesis, tumor progression and on the response to therapy. To this end, we use next generation sequencing, GWAS, epigenomic data to decode the tumor genome and identify cancer genes, followed by functional genomic studies. Computational analyses of large genome datasets are used to unravel novel genetic mechanisms underlying carcinogenesis.

The main objectives of our research are

1. Identification of inherited genetic variation that predisposes to the development of neuroblastoma through large-scale genome analysis. We apply computational analyses of whole exome sequencing data from a large set of patients with cancers and healthy controls to study the burden of pathogenic variants in genes of clinical importance.
2. Explore the role of somatic noncoding mutations affecting binding sites of transcription factor that are key regulators of neuroblastoma core regulatory circuitry by computational analysis of data from whole genome sequencing data and from methods to identify functional DNA elements such as ATAC-seq and HiC assays, assays of DNA methylation, and immunoprecipitation (IP) of proteins that interact with DNA and RNA, i.e., modified histones, transcription factors, chromatin regulators, and RNA-binding proteins, followed by sequencing.
3. Decipher how single-cell gene expression, before and after chemotherapy, affects survival, proliferation and therapeutic treatment response of neuroblastoma cells. We will apply algorithms on single cells RNAseq data from neuroblastoma resistant-cell to identify "causal genes" liable of neuroblastoma resistant-cell selection and survival.

Final goal of this project is to develop individualized care for children with cancer using genomic biomarkers that allow a precise risk stratification and the development a personalized treatment.

Supervisor(s), Lab/Group details, other additional info.

The major interest of the Supervisor is to study the genetic basis of cancer. His research interests are focused on translational genomics in pediatric cancers. He has the expertise in the analysis of genomic data obtained by diverse methodological approaches such as SNP array, Gene Expression array, Next Generation Sequencing. He also has competence in the application of statistical methods to a wide range of topics in biology. It encompasses the



design of biological experiments, the collection and analysis of data from experiments and the interpretation of the results. The Supervisor is currently the Head of the Bioinformatic Service for NGS at CEINGE Biotecnologie Avanzate.

Supervisor's Laboratory is located at CEINGE Biotecnologie Avanzate and his Group is composed of 3 Post-docs whom 1 bioinformatician, 2 PhD students, 5 fellows whom 2 bioinformaticians and 2 ungraduated students. The team members have competences in different disciplines such as bioinformatics, functional genomics, molecular biology, and cancer genetics. The candidate will find a multidisciplinary environment and qualified team members for his / her training growth in bioinformatics, in genetics and biology.

The candidate should be motivated to acquire knowledge on algorithms for the analysis of next generation sequencing, microarray, GWAS and epigenomic data but also knowledge related to genetics and biology in order to achieve a complete training that will enable him / her to be able to perform bioinformatic analyses but also to interpret the results.

Funding

1. 2019-2022: NIH, ID: R01 CA124709-06, (USA), Budget: 29,000 euro, Co-Investigator, "The Genetic Basis of Neuroblastoma Tumorigenesis".
2. 2017-2020: AIRC - Italian Association for Cancer Research, ID: 19255, Budget: € 294,000, Principal Investigator, "Understanding the shared genetic and biological basis among neural crest cells-derived tumors".
3. 2018-2021: OPEN the Association of Pediatric Oncology and Neuroblastoma, Budget: 150,000 €, Principal Investigator, "Liquid biopsy for the care of children with pediatric solid tumors".
4. 2018-2021: Ministry of Health, GR-2016-02364546 Budget: 82,500 €, Co-Investigator, "Advanced therapeutic medicinal product based on CD30-specific chimeric antigen receptor (CAR) T cells for treatment of patients with relapsed / refractory CD30 + lymphomas".
5. 2020-2022: Italian Foundation for the Fight against Neuroblastoma, Budget: € 281,000, Principal Investigator, "GENEDREN".
6. 2020/2022: PRIN, Budget: 110,000 €, Co-Investigator. "Morphological biomarkers for early diagnosis in oncology – MORFEO"

References

1. Lasorsa VA, Cimmino F, Ognibene M, Mazzocco K, Erminio G, Morini M, Conte M, Iolascon A, Pezzolo A, **Capasso M**. 19p Loss Is Significantly Enriched in Older Age Neuroblastoma Patients and Correlates With Poor Prognosis. *NPJ Genom Med*. 2020 Apr 15;5:18.
2. **Capasso M**, Lasorsa VA, Cimmino F, Avitabile M, Cantalupo S, Montella A, De Angelis B, Morini M, de Torres C, Castellano A, Locatelli F, Iolascon A. Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. *Cancer Res*. 2020 Feb 1;80(3):382-393.
3. Avitabile M, Succio M, Testori A, Cardinale A, Vaksman Z, Lasorsa VA, Cantalupo S, Esposito M, Cimmino F, Montella A, Formicola D, Koster J, Andreotti V, Ghiorzo P, Romano MF, Staibano S, Scalvenzi M, Ayala F, Hakonarson H, Corrias MV, Devoto M, Law MH, Iles MM, Brown K, Diskin S, Zambrano N, Iolascon A, **Capasso M**. Neural Crest-Derived Tumor Neuroblastoma and Melanoma Share 1p13.2 as Susceptibility



- Locus That Shows a Long-Range Interaction With the SLC16A1 Gene. *Carcinogenesis*. 2020 May 14;41(3):284-295.
4. Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, **Capasso M**. Fine Mapping of 2q35 High-Risk Neuroblastoma Locus Reveals Independent Functional Risk Variants and Suggests Full-Length BARD1 as Tumor-Suppressor. *Int J Cancer*. 2018 Dec 1;143(11):2828-2837.
 5. Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, **Capasso M**. Kinome Expression Profiling of Human Neuroblastoma Tumors Identifies Potential Drug Targets for Ultra High-Risk Patients. *Carcinogenesis*. 2017 Oct 1;38(10):1011-1020
 6. Formicola D, Petrosino G, Lasorsa VA, Pignataro P, Cimmino F, Vetrella S, Longo L, Tonini GP, Oberthuer A, Iolascon A, Fischer M, **Capasso M**. An 18 Gene Expression-Based Score Classifier Predicts the Clinical Outcome in Stage 4 Neuroblastoma. *J Transl Med*. 2016 May 17;14(1):142.
 7. Lasorsa VA, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, Esposito MR, Pantile M, Zanon C, De Mariano M, Longo L, Hogarty MD, de Torres C, Tonini GP, Iolascon A, **Capasso M**. Exome and Deep Sequencing of Clinically Aggressive Neuroblastoma Reveal Somatic Mutations That Affect Key Pathways Involved in Cancer Progression. *Oncotarget*. 2016 Apr 19;7(16):21840-52.
 8. **Capasso M**, Diskin S, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, Iolascon A, Devoto M, Maris JM. Common Genetic Variants in NEFL Influence Gene Expression and Neuroblastoma Risk. *Cancer Res*. 2014 Dec 1;74(23):6913-24
 9. Diskin SJ, **Capasso M**, Schnepf RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, Jagannathan J, Latorre V, Iolascon A, Hakonarson H, Devoto M, Maris JM. Common Variation at 6q16 Within HACE1 and LIN28B Influences Susceptibility to Neuroblastoma. *Nat Genet*. 2012 Oct;44(10):1126-30.
 10. **Capasso M**, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter C, Bradfield JP, Scott RH, Jagannathan J, Garris M, McConville C, London WB, Seeger RC, Grant SF, Li H, Rahman N, Rappaport E, Hakonarson H, Maris JM. Common Variations in BARD1 Influence Susceptibility to High-Risk Neuroblastoma. *Nat Genet*. 2009 Jun;41(6):718-23.